-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostatecancer. J Natl Cancer Inst . 2004;96:879-882. 7. Berenson JR, Hillner BE, Kyle RA, et al. American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol . 2002;20:3719-3736. 8. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol . 2005;17:462-466. 9. Medical economics. Physicians’ Desk Reference. 57th ed. Montvale, NJ: Medical Economics
antibody inhibiting osteoclast differentiation,
activation, and survival with applicable suppression of bone turnover in patients with multiple
myeloma, osteolytic bone disease, and bone metastases from breast and prostatecancer.
It is also a useful drug for managing the GCT of bone and one excellent option in metastatic GCT.
The long time safety and complications, especially in young female patients, are to be proven.
Conclusions. Early diagnosis and accurate management of GCT are mandatory in order to achieve
good long-term clinical results. Denosumab treatment
REFERENCES 1. Hatano K, Fujita S, Tsujimoto Y, et al. Rare case of the hyaline vascular type of Castlemans’s disease of the kidney. International Journal of Urology . 2007;14:1098-1100. 2. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer . 1956;9:822-830. 3. Guthrie PJ, Thomas JV, Peker D, Turkbey B, Rais-Bahrami S. Perivesical unicentric Castleman disease initially suspected to be metastatic prostatecancer. Urol Ann . 2016;8:245-248. 4. Vassos N, Raptis D, Lell M, et al. Intra-abdominal localized
. Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R et al. Multidisciplinary approach to the treatment of bone metastases: Osteo-oncology center, a new organizational model. Tumori. 2009; 95:291–297. 6. Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostatecancer patients: A population-based study. Int. Urol. Nephrol. 2018; 50:71–78. 7. Plunkett TA
, Costerton JW, Sedghizadeh PP. The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep . 2010;8:40-48. 11. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporosis International . 2013;24:237-244. 12. Walter C, Al-Nawas B, Grotz KA, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostatecancer patients with advanced disease
prior to coronary revascularisation? Heart Lung Circ . 2012;21:468-479. 30. Xi L, Rui X, Zhang B, Gao F. MRI tracking stem cells transplantation for coronary heart disease. Pak J Med Sci . 2014;30:899-903. 31. Sterenczak KA, Meier M, Glage S, et al. Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostatecancer. BMC Cancer . 2012;12:284. 32. Guenoun J, Koning GA, Doeswijk G, et al. Cationic Gd-DTPA liposomes for highly
electrophoresis. Forensic Sci Int Genet Suppl Ser . 2013;4:e274-e275. 26. Kuner R, Brase JC, Sültmann H, Wuttig D: microRNA biomarkers in body fluids of prostatecancer patients. Methods . 2013;59:132-137. 27. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One . 2008;3:1-7. 28. Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res . 2010;12:R90. 29. Guo Z, Maki M, Ding R, Yang Y, Zhang B, Xiong L. Genome
. The overlap may be explained by the existence of a common myelin epitope in the peripheral nervous system (PNS) and the central nervous system (CNS) that is subjected to immune-mediated self-aggression [ 6 , 12 ]. Cases of GBS triggered by surgery have previously been reported to occur in the first eight weeks after the procedure, especially in patients with a history of neoplastic disease (gastrointestinal carcinoma, blood and skin cancers, prostatecancer, or gynaecological cancer) or a positive history of other autoimmune diseases (Sjögren syndrome, giant